IBA Receives FDA Approval of its New Compact Gantry Clearing the way for Proteus®ONE

Louvain-la-Neuve, Belgium, July 16th, 2014 - IBA (Ion Beam Applications SA), the world’s leading provider of proton therapy solutions for the treatment of cancer, announces that it has received Marketing Authorization from the U.S. Food and Drug Administration (FDA) for its Compact Gantry Beam Line (CGBL: FDA 510(k) K132919). IBA anticipates that this regulatory approval will intensify the international interest in Proteus®ONE*, IBA’s next generation proton therapy compact system.
Read more Read more

Proteus®ONE is IBA’s single-room proton therapy system which is smaller, less expensive, faster to install and encompasses the latest in targeted proton therapy technologies, including IBA’s Intensity Modulated Proton Therapy (IMPT). IBA created the Proteus®ONE system to allow more patients access to proton therapy globally and has already sold five Proteus®ONE systems in Shreveport, Louisiana (USA), Nice (France), Taiwan (China) and two in Japan.

Olivier Legrain, Chief Executive Officer of IBA commented: “We are delighted to have received Marketing Authorization from the FDA for the Proteus®ONE Compact Gantry. This is an exciting milestone for our customers in North America, where the cost of healthcare is a major focus. The Proteus®ONE aligns with the US healthcare trend of providing the highest quality of cancer treatment possible at the best possible price. We are confident that Proteus®ONE will drive greater momentum in the adoption of this next generation targeted cancer treatment internationally. The approval reaffirms our world leading position in the delivery of highly targeted, safer cancer treatment solutions. We very much look forward to the first patients at the Willis-Knighton Cancer Centre in the US benefitting from our compact proton therapy offering later this year.”

Lane R. Rosen, MD, Director of Radiation Oncology at the Willis-Knighton Cancer Centre, added: “We are very excited to have Intensity Modulated Proton Therapy become an available option for our patients. The complete clearance of the Proteus®ONE system, installed at Willis-Knighton, is yet another milestone demonstrating how IBA and WKCC partner for progress.”

* Proteus®ONE is the brand name of a new configuration of the Proteus® 235.

Notes to Editors

About IBA

IBA (Ion Beam Applications S.A.) is a cancer diagnostics and treatment equipment company, and the worldwide technology leader in the field of proton therapy, the most advanced form of radiotherapy available today.

The Company’s primary expertise lies in the development of next generation proton therapy technologies that provide oncology care providers with premium quality services and equipment. IBA’s proton therapy solutions are scalable and adaptable, offering universal full scale proton therapy centers as well as next generation compact, single room solutions. IBA also focuses on the development and supply of dosimetry solutions for Quality Assurance of medical equipment and increased patient safety as well as particle accelerators for medical and industrial applications.

Headquartered in Belgium and employing more than 1,000 people worldwide, IBA currently has installed systems across Europe and the US and is expanding into emerging markets. The Company is focused on building sustainable global growth for investors, providing solutions in the fight against cancer.

IBA is listed on the pan-European stock exchange EURONEXT. (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB) and more information can be found at: www.iba-worldwide.com

About the Willis-Knighton Cancer Center

Located in Shreveport Louisiana, the Willis-Knighton Cancer Center (WKCC) is the region’s premier cancer treatment facility. WKCC provides a wide range of treatment options for cancer patients including radiation oncology, medical oncology and hematology, surgical oncology and gynecologic oncology. The Cancer Center provides diagnostic services such as PET, X-ray, CT and laboratory. It also offers support groups, counseling, nutritional and educational resources, and community education programs.

For further information please contact:


Jean-Marc Bothy
Chief Financial Officer
+32 10 475 890

Thomas Ralet
Vice-President Corporate Communication
+32 10 475 890

Willis Knighton Cancer Center

Marilyn Joiner
Director of Marketing & Public Relations
+1 318 212-8965

For media and investor enquiries:

Consilium Strategic Communications
Amber Bielecka, Mary-Jane Elliott, Matthew Neal, Jessica Hodgson, Ivar Milligan
+44 (0) 20 3709 5700